Neumora Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2023 | $-33.0M | $-33.1M | $36.0K | $2.2M |
| Jun 2023 | $-31.0M | $-31.0M | $0 | $2.5M |
| Sep 2023 | $-47.8M | $-47.8M | $37.0K | $6.5M |
| Dec 2023 | $-51.4M | $-51.5M | $44.0K | $6.1M |
| Mar 2024 | $-43.0M | $-43.0M | — | $7.4M |
| Jun 2024 | $-56.2M | $-56.2M | — | $12.8M |
| Sep 2024 | $-33.5M | $-33.5M | — | $9.9M |
| Dec 2024 | $-50.3M | $-50.3M | — | $9.9M |
| Mar 2025 | $-59.4M | $-59.4M | — | $9.3M |
| Jun 2025 | $-52.4M | $-52.4M | — | $7.2M |
| Sep 2025 | $-46.6M | $-46.6M | — | $6.0M |
| Dec 2025 | $-48.0M | $-48.0M | — | $7.4M |
| Mar 2026 | $-46.4M | $-46.4M | — | $7.4M |
| Jun 2026 | $-39.5M | $-39.5M | — | $7.2M |